Andrey A. Meshcheryakov

Andrey A. Meshcheryakov

Auto-generated profile, based on publicly available information

Andrey A. Meshcheryakov

Blokhin National Medical Research Center of Oncology

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
Hans Joachim SchmollHans Joachim Schmoll
Hans Joachim Schmoll
ECE. Van Cutsem
E. Van Cutsem
ASA. Stein
A. Stein
VVVincenzo Valentini
Vincenzo Valentini
BGB. Glimelius
B. Glimelius
Andres CervantesAndres Cervantes
Andres Cervantes
Colorectal cancer (CRC) is the most common tumour type in both sexes combined in Western countries. Although screening programmes including the implementation of faecal occult blood test and colonoscopy might be able to reduce mortality by removing precursor lesions and by making diagnosis at an earlier stage, the burden of disease and mortality is still high. Improvement of diagnostic and treatment options increased staging accuracy, functional outcome for early stages as well as survival. Although high quality surgery is still the mainstay of curative treatment, the management of CRC must be a multi-modal approach performed by an experienced multi-disciplinary expert team. Optimal choice of the individual treatment modality according to disease localization and extent, tumour biology and patient factors is able to maintain quality of life, enables long-term survival and even cure in selected patients by a combination of chemotherapy and surgery. Treatment decisions must be based on the available evidence, which has been the basis for this consensus conference-based guideline delivering a clear proposal for diagnostic and treatment measures in each stage of rectal and colon cancer and the individual clinical situations. This ESMO guideline is recommended to be used as the basis for treatment and management decisions.

20 November 2020 in Journal of Clinical Oncology
Verified
Journal Article
Open access
AEAlexander M. M. Eggermont
Alexander M. M. Eggermont
CBChristian U. Blank
Christian U. Blank
MMMario Mandala
Mario Mandala
GLGeorgina Venetia Long
Georgina Venetia Long
VAVictoria G. Atkinson
Victoria G. Atkinson
Caroline RobertCaroline Robert
Caroline Robert
PURPOSE: We conducted the phase III double-blind European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. On the basis of 351 recurrence-free survival (RFS) events at a 1.25-year median follow-up, pembrolizumab prolonged RFS (hazard ratio [HR], 0.57; P < .0001) compared with placebo. This led to the approval of pembrolizumab adjuvant treatment by the European Medicines Agency and US Food and Drug Administration. Here, we report an updated RFS analysis at the 3.05-year median follow-up. PATIENTS AND METHODS: A total of 1,019 patients with complete lymph node dissection of American Joint Committee on Cancer Staging Manual (seventh edition; AJCC-7), stage IIIA (at least one lymph node metastasis > 1 mm), IIIB, or IIIC (without in-transit metastasis) cutaneous melanoma were randomly assigned to receive pembrolizumab at a flat dose of 200 mg (n = 514) or placebo (n = 505) every 3 weeks for 1 year or until disease recurrence or unacceptable toxicity. The two coprimary end points were RFS in the overall population and in those with programmed death-ligand 1 (PD-L1)–positive tumors. RESULTS: Pembrolizumab (190 RFS events) compared with placebo (283 RFS events) resulted in prolonged RFS in the overall population (3-year RFS rate, 63.7% v 44.1% for pembrolizumab v placebo, respectively; HR, 0.56; 95% CI, 0.47 to 0.68) and in the PD-L1–positive tumor subgroup (HR, 0.57; 99% CI, 0.43 to 0.74). The impact of pembrolizumab on RFS was similar in subgroups, in particular according to AJCC-7 and AJCC-8 staging, and BRAF mutation status (HR, 0.51 [99% CI, 0.36 to 0.73] v 0.66 [99% CI, 0.46 to 0.95] for V600E/K v wild type). CONCLUSION: In resected high-risk stage III melanoma, pembrolizumab adjuvant therapy provided a sustained and clinically meaningful improvement in RFS at 3-year median follow-up. This improvement was consistent across subgroups.

24 June 2005 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
YSYuriy V. Shebzukhov
Yuriy V. Shebzukhov
EKEkaterina P. Koroleva
Ekaterina P. Koroleva
SKSvetlana V. Khlgatian
Svetlana V. Khlgatian
PBPavel V. Belousov
Pavel V. Belousov
KKKsenia E. Kuz'Mina
Ksenia E. Kuz'Mina
SNSergei A. Nedospasov
Sergei A. Nedospasov
Antibodies to cancer antigens can often be detected in the sera of patients, although the mechanism of the underlying humoral immune response is poorly understood. Using immunoscreening of tumor‐derived cDNA expression libraries (SEREX), we identified human histone deacetylase 3 (HDAC3) as serologically defined antigen in colon cancer. Closely related HDAC1 and HDAC2 do not elicit humoral response in colon cancer patients. We show that the C‐terminal region of HDAC3 protein lacking the homology to other Class I HDAC contains at least 3 distinct B‐cell epitopes that are recognized by the serum antibodies. HDAC3 in combination with other SEREX antigens may become a useful molecular biomarker with diagnostic or prognostic value for a subset of colon cancer patients. Supplementary material for this article can be found on the International Journal of Cancer website at http://www.interscience. wiley.com/jpages/0020‐7136/suppmat/index.html.

15 August 2005 in Immunology Letters
Verified
Journal Article
Closed access
YSYuriy V. Shebzukhov
Yuriy V. Shebzukhov
EKEkaterina P. Koroleva
Ekaterina P. Koroleva
SKSvetlana V. Khlgatian
Svetlana V. Khlgatian
MLMaria A. Lagarkova
Maria A. Lagarkova
AMAndrey A. Meshcheryakov
Andrey A. Meshcheryakov
SNSergei A. Nedospasov
Sergei A. Nedospasov

2 September 2014 in Future Oncology
Verified
Journal Article
Open access
SYSuayib Yalcin
Suayib Yalcin
DTDiaeddine Trad
Diaeddine Trad
YKYasser Abdel Kader
Yasser Abdel Kader
HHHafez Halawani
Hafez Halawani
ODOsman Gokhan Demir
Osman Gokhan Demir
CKClaus-Henning Köhne
Claus-Henning Köhne
The VEGF- (bevacizumab) and EGFR- (cetuximab and panitumumab) targeting monoclonal antibodies have become integral components of the first-line treatment strategies for patients with metastatic colorectal cancer (mCRC). Increasingly combination chemotherapy, with or without a targeted agent, is being used to facilitate curative liver resection and improve survival rates in patients with initially unresectable but potentially resectable mCRC. Currently, the only selective marker for the treatment of patients with mCRC is tumor RAS mutational status. BRAF status is a strong prognostic indicator. Medical and clinical oncologists from Central Asia, Russia, the Middle East, Africa and Turkey reviewed data for the use of targeted agents in the treatment of patients with mCRC and have formed recommendations for the biological of choice first-line for patients with mCRC.

17 November 2020 in Tumors of female reproductive system
Verified
Journal Article
Open access
PDF file
OGO. O. Gordeeva
O. O. Gordeeva
IKI. V. Kolyadina
I. V. Kolyadina
LZLiudmila Zhukova
Liudmila Zhukova
IGI. P. Ganshina
I. P. Ganshina
GVG. V. Vyshinskaya
G. V. Vyshinskaya
AMA. A. Meshcheryakov
A. A. Meshcheryakov
Background. Treatment results for the patients with stage II–III triple negative breast cancer (TN BC) have to be improved. Not only the new treatment regimens, but new predictive and prognostic factors should to be developed.Materials and methods. We included 98 patients with stage II–III TN BC in our study. We studied efficacy and safety of PlaTax regimen (cisplatin 75 mg / m2 day 1 + paclitaxel 80 mg / m2 days 1, 8, 15, course every 4 weeks) in this cohort of patients. We assessed pathologic response, survival and factors, which were relevant for predicting response and prognose survival.Results. PlaTax regimen is characterized by high efficacy and tolerable toxicity. Clinical efficacy was 85.8 %, pCR achievement was 60.5 %, tpCR achievement was 58.1 %. The regimen has low haematological toxicity (neutropenia III–IV grades – 4.1 %); the most frequent adverse events were polyneuropathy (18.5 %) and decreased renal function (24.5 %). 3-year progression-free survival was 68.4 %, most of the relapses (92 %) occurred during first 2 years. 3 year overall survival was 77.6 %. The most relevant predictive factor was level of Ki-67 ≥50 % (pCR 38.5 % vs. 68.7 %, p = 0.038). pCR achievement was the most important prognostic factor, resulting in improved 3-year progressionfree survival (44.3 % vs. 89.1 %, p 0.0001), and 3-year overall survival (61.5 % vs. 91.6 %, p = 0.001). Not only the residual disease, but also the size of residual tumor was important from prognostic point of view. Other important prognostic factors were size of the tumor, status of regional lymph nodes, grade. Delay in surgical treatment more than a month lead to decreased 3-year progression-free survival: 87.1 % vs. 62.5 % (p = 0.047).Conclusions. Our data suggest that studied regimen could be an option for patients with stage II–III TN BC. The assessment of the predictive and prognostic factors will help improve the treatment results for patients with stage II–III TN BC.